Latest news

• Gilead makes a play for novel cancer drug with Tizona deal

  In March, Gilead also signed a $4.9bn deal to acquire Forty Seven, a company that specialises in cancer immunotherapies targeting the CD47 immune checkpoint.

• Gilead and Arcus complete closing of ten-year immunotherapy partnership

  That includes a $4.9bn deal signed in March to acquire Forty Seven, a company that specialises in cancer immunotherapies targeting the CD47 immune checkpoint.

• Gilead swoops on Forty Seven with $4.9bn all-cash deal

  Gilead is paying $95.50 per share for Forty Seven and its lead drug magrolimab, a 60% premium to the biotech’s closing share price on Friday, although shares in the ... Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma,

• China’s Innovent to start US trials of anti-CD47 cancer drug

  Innovent is facing some well-positioned competition in the CD47 space. A US biotech – Stanford University spinout Forty Seven – is advancing a CD47-targeting antibody called Hu5F9-G4 in mid-stage

• Bluebird and Celgene BCMA CAR-T kicks off ASCO

  varlilumab, Forty Seven’s anti-CD47 drug Hu5F9-G4 and CD122-biased agonist NKTR-214 from Nektar, to name just a few.